The percentage of serious fatal and non-fatal infections was, however, higher in the CYC group (15.63% vs 3.7%, the per cent difference adjusted for baseline proteinuria 13.35 (95% CI 0.3 to 26.4), p=0.04).
enteric-coated mycophenolate sodium (EC-MPS) 1440?mg/day for first 6?months
intravenous cyclophosphamide (CYC) 0.5–1?g/m2 monthly
Composites of unfavourable outcomes (death, doubling of serum creatinine, non-remission and intolerance to treatment)